Effects of fenofibrate therapy on plasma ubiquinol-10 and ubiquinone-10 levels in Japanese patients with hyperlipidemia and type 2 diabetes mellitus.

Abstract

STUDY OBJECTIVE:

To assess the effects of fenofibrate therapy on concentrations of plasma ubiquinol-10 and ubiquinone-10-the reduced and oxidized forms, respectively, of coenzyme Q(10).

DESIGN:

Prospective, open-label, non-controlled study.

SETTING:

University clinic and laboratory.

PATIENTS:

Eighteen patients with hyperlipidemia and type 2 diabetes mellitus.

INTERVENTION:

Patients received fenofibrate 150 mg/day for 12 weeks.

MEASUREMENTS AND MAIN RESULTS:

Metabolic parameters were assessed 4, 8, and 12 weeks after the start of fenofibrate treatment. Plasma ubiquinol-10 and ubiquinone-10 levels were measured by reverse-phase high-performance liquid chromatography. At 4, 8, and 12 weeks, significant reductions in fasting triglyceride levels and significant increases in high-density lipoprotein cholesterol levels were noted. Total cholesterol, low-density lipoprotein cholesterol, fasting plasma glucose, and adiponectin levels, however, did not change significantly. Plasma ubiquinol-10 concentrations significantly increased after 8 and 12 weeks (p<0.05 for both), whereas ubiquinone-10 concentrations tended to decrease, especially at 12 weeks.

CONCLUSION:

Our findings suggest that fenofibrate may help produce energy or prevent oxidation by increasing plasma ubiquinol-10 concentration; this effect may protect against the development and progression of atherosclerosis. In addition, treatment with fenofibrate demonstrated a favorable effect on serum lipid parameters.

• Authors: Akimichi Asano, Junji Kobayashi, Yuko Murase, Atsushi Nohara, Masa-Aki Kawashiri, Akihiro Inazu, Masami Shimizu, Hiroshi Mabuchi
• Journal: Pharmacotherapy (Pharmacotherapy) Vol. 26 Issue 4 Pg. 447-51 (Apr 2006) ISSN: 0277-0008 [Print] United States
• PMID: 16553501 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Coenzymes
• Ubiquinone
• ubiquinol-10
• coenzyme Q10
• Fenofibrate

Topics

• Coenzymes
• Diabetes Mellitus, Type 2 (physiopathology)
• Disease Progression
• Female
• Fenofibrate (blood, pharmacology)
• Humans
• Hyperlipidemias (drug therapy, physiopathology)
• Male
• Middle Aged
• Prospective Studies
• Ubiquinone (analogs & derivatives, blood, drug effects)